Clinical trials: Neoplasms Recurrence
Breast Neoplasms
A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer
The primary purpose of this study is to evaluate the tolerability and safety of E7090 as monotherapy and in combination with other anticancer agents in participants with ER+, HER2- recurrent/metastatic breast cancer and to…
- Trial name
- NCT04572295
- Testing
- E7090, Fulvestrant, Exemestane
- Where
- 11 sites in Japan
- Volunteers
- 51 people
- Sponsor
- Eisai Co., Ltd.
Relapsed or Refractory Multiple Myeloma
Clinical Study of O&D-001 Injection in the Treatment of Relapsed or Refractory Multiple Myeloma
This study is a single-center, open and dose-escalation clinical study to evaluate the safety, tolerability, PK/PD characteristics and preliminary efficacy of the investigational drug O\&D-001 injection in the treatment of…
- Trial name
- NCT07369895
- Testing
- Chimeric antigen receptor T cell O&D-001 injection targeting BCMA and GPRC5D
- Where
- China
- Volunteers
- 18 people
- Sponsor
- O&D BioTech Group CO., Limited
Multiple Myeloma
Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma
The purpose of this study is to determine 1) the safety and tolerability of multiple intravenous doses of anti-CXCR4 (BMS-936564) as monotherapy and as combination, and 2) the maximum tolerated dose (MTD) of BMS-936564 in…
- Trial name
- NCT01359657
- Testing
- Anti-CXCR4 (BMS-936564), Lenalidomide, Dexamethasone
- Where
- 4 sites in United States
- Volunteers
- 46 people
- Sponsor
- Bristol-Myers Squibb
Non Endometrioid Carcinoma, Endometrioid Carcinoma
Evaluation of Sentinel Node Policy in Early Stage Endometrial Carcinomas at Intermediate and High Risk of Recurrence.
The aim of this trial is to evaluate the sentinel node policy in early stage endometrial carcinomas at intermediate and high risk of recurrence (by comparing the sentinel node policy to current initial staging protocols).
- Trial name
- SENTIRAD (NCT02598219)
- Testing
- Pre-operative SN mapping with radionucleide, Intra-operative SN mapping with patent V blue dye, Intra-operative SN mapping with indocyanin green
- Where
- 16 sites in France
- Volunteers
- 262 people
- Sponsor
- Centre Oscar Lambret
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
Perceptions of Burden in Patients With Late-Stage Cancer and Their Caregivers
RATIONALE: Gathering information over time about patients' sense of being a burden on their caregiver, and caregivers' sense of burden on themselves, may help doctors learn more about the desire to die in patients with late-stage…
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Depression, Leukemia
- Trial name
- NCT00770419
- Testing
- medical chart review, questionnaire administration, psychosocial assessment and care
- Sponsor
- Rutgers, The State University of New Jersey
Breast Neoplasms
A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of Recurrence
This non-interventional observational study evaluates the real-world effectiveness and safety profile of ribociclib in combination with an aromatase inhibitor for adjuvant treatment in patients with HR+/HER2- early breast cancer…
- Trial name
- CAROLEEN (NCT06830720)
- Testing
- ribociclib + AI ± LHRH, abemaciclib + ET ± LHRH, ET mono ± LHRH
- Where
- 287 sites in Austria, Germany
- Volunteers
- 3,250 people
- Sponsor
- Novartis Pharmaceuticals
Anemia, Leukemia
Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer
RATIONALE: Darbepoetin alfa and epoetin alfa may stimulate red blood cell production and treat anemia in patients who are receiving chemotherapy.
- Conditions
- Anemia, Leukemia, Lymphoma, Lymphoproliferative Disorder
- Trial name
- NCT00070382
- Testing
- darbepoetin alfa, epoetin alfa
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Cervical Cancer Recurrent
Efficacy and Safety of AK104 Combined With Chemotherapy and Recombinant Human Adenovirus 5 Injection in Cervical Cancer
In order to improve the clinical effect and find a new safe and effective treatment model for advanced recurrent cervical cancer, this study explored the efficacy level safety of pemetrexed, carboplatin, recombinant human…
- Trial name
- NCT06455046
- Testing
- AK104, Recombinant Human Adenovirus 5 Injection
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Fujian Cancer Hospital
HNSCC, Head and Neck Neoplasms
Phase II Study of Durvalumab(MEDI4736) + Tremelimumab in Pulmonary Sarcomatoid Carcinoma
Phase II study of Durvalumab+/- Tremelimumab in patients with recurred metastatic head and neck squamous cell carcinoma
- Trial name
- NCT06446570
- Testing
- Durvalumab,Tremelimumab
- Where
- South Korea
- Volunteers
- 18 people
- Sponsor
- Seoul National University Hospital
Recurrent/Metastatic Gastric Cancer
Phase Ib/II Study to Evaluate the Safety and Efficacy of Nivolumab in Combination With Paclitaxel in Epstein-Barr Virus(EBV)-Related, or Microsatellite Instability-High (MSI-H), or Programmed Cell Death Ligand 1 (PD-L1) Positive Advanced Gastric Cancer
This is a Phase Ib/II study to identify the recommended dose of paclitaxel and nivolumab for further study, and to assess the safety and clinical efficacy of this combined treatment in EBV-related, MSI-high, or PD-L1 positive…
- Trial name
- NCT05535569
- Testing
- Nivolumab, Paclitaxel
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- Yonsei University
Head and Neck Cancer Squamous Cell
Reirradiation and Erbitux in the HNSCC
The purpose of this study is to investigate in patients with cancer of the throat and recurrent inoperable a different modality treatment consisting of radiation continuously for 5 weeks and half associated with a drug directed…
- Trial name
- NCT01237483
- Testing
- Erbitux
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Groupe Oncologie Radiotherapie Tete et Cou
Prostate Cancer
Focal Salvage Brachytherapy Study (FocaSaBra)
The aim of this prospective phase II study is to evaluate the toxicity of salvage partial (focal) prostate brachytherapy in patients after prior radiotherapy (standard teleradiotherapy with / without brachytherapy…
- Trial name
- FocaSaBra (NCT05715502)
- Testing
- brachytherapy
- Where
- Poland
- Volunteers
- 100 people
- Sponsor
- The Greater Poland Cancer Centre
Endometrial Cancer
Letrozole in Treating Women With Recurrent or Metastatic Endometrial Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of letrozole in treating women who have recurrent or…
- Trial name
- NCT00004251
- Testing
- letrozole
- Volunteers
- 33 people
- Sponsor
- NCIC Clinical Trials Group
NHL, Relapsed, Adult, B-cell Lymphoma
Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies
This study is a multi-center study to evaluate the safety of KUR-502 in subjects with refractory/relapsed B-cell NHL or leukemia (ALL or CLL).
- Conditions
- NHL, Relapsed, Adult, B-cell Lymphoma, B-cell Leukemia, DLBCL - Diffuse Large B Cell Lymphoma
- Trial name
- ANCHOR2 (NCT05487651)
- Testing
- KUR-502
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Athenex, Inc.
Epithelial Ovarian Cancer, Relapse
Tri Association in Patient With Advanced Epithelial Ovarian Cancer in Relapse
Assessing the safety and efficacy of the bevacizumab, Olaparib and Durvalumab (MEDI 4736) combination in patient with high grade serous or high grade endometrioid or other high grade epithelial non mucinous ovarian tumor, with at…
- Trial name
- BOLD (NCT04015739)
- Testing
- Bevacizumab, Olaparib and Durvalumab (MEDI 4736) combination
- Where
- 9 sites in France
- Volunteers
- 74 people
- Sponsor
- ARCAGY/ GINECO GROUP
Lymphoma, Precancerous/Nonmalignant Condition
Zidovudine, Interferon Alfa-2b, PEG-Interferon Alfa-2b in Patients With HTLV-I Associated Adult T-Cell Leukemia/Lymphoma
RATIONALE: Human T-cell lymphotropic virus type 1 (HTLV-1) can cause cancer. Zidovudine is an antiviral drug that acts against the human T-cell lymphotropic virus type 1.
- Trial name
- NCT00854581
- Testing
- PEG-interferon alfa-2b, Interferon alfa-2b, Valproic Acid
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Miami
DLBCL, MCL
Peptide Receptor Radionuclide Therapy With 90Y-Dotatoc in Relapsed/Refractory Diffuse Large B Cell and Mantle Cell Lymphomas
This is a prospective, single arm,single centre open-label, phase II study in relapsed or refractory DLBCL and MCL non-Hodgkin's lymphoma (NHL), not suitable to other therapies, included HDCT, or patients relapsed after high-dose…
- Conditions
- DLBCL, MCL, Recurrent Disease
- Trial name
- itTRIOlym (NCT02488512)
- Testing
- 90Y-DOTATOC
- Where
- Italy
- Volunteers
- 1 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Relapsed and Refractory Multiple Myeloma (RRMM)
Real-World Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma
Primary Objective: 1. To describe the distribution of treatment regimens and objective response rate (ORR) in a Benchmark Cohort of real-world patients with relapsed/refractory multiple myeloma (RRMM) who initiate treatment after…
- Trial name
- NCT05673967
- Testing
- Non-Interventional
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Regeneron Pharmaceuticals
Cervical Cancer
MR- PET Guided Biologically Optimised Interstitial Brachytherapy
The proposed two stage study will evaluate patterns of local recurrence after EBRT and brachytherapy in spatial reference to baseline functional MRI and FLT/F-Miso PET scan in patients undergoing chemoradiotherapy for…
- Trial name
- MR-PET Brachy (NCT01391065)
- Testing
- MR PET Guided Brachytherapy
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Tata Memorial Hospital
Breast Cancer, Recurrent Breast Cancer
Acupuncture in Treating Women With Stage I, Stage II, or Stage III Breast Cancer With Aromatase Inhibitor-Related Joint Pain
RATIONALE: Acupuncture may help relieve moderate or severe joint pain caused by aromatase inhibitors. PURPOSE: This randomized phase II trial is studying acupuncture in treating women with stage I, stage II, or stage III breast…
- Conditions
- Breast Cancer, Recurrent Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer
- Trial name
- NCT01013337
- Testing
- acupuncture therapy
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.